Webinar 5

Hepatitis D Virus: Virology, Epidemiology, Clinical Features, Diagnosis, Management, Therapy
A Virtual Symposium
Thursday, September 9th, 3-5 pm ET

Program and Speaker Bios
Hepatitis D Virus: Virology, Epidemiology, Clinical Features, Diagnosis, Management, Therapy
A Virtual Symposium

Presentations

Introduction & Welcome
Dr. Jay Hoofnagle, Director, Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, NIDDK, NIH

HDV Virology
Dr. Jeffrey Glenn, Professor of Medicine (Gastroenterology and Hepatology) & of Microbiology Immunology, Stanford University

HDV Clinical Features/Epidemiology
Dr. Norah Terrault, Professor of Medicine & Chief of Gastroenterology & Liver Diseases, Keck School of Medicine at the University of Southern California

HDV Therapies
Dr. Theo Heller, Chief of Translational Hepatology Section, Liver Diseases Branch, NIDDK, NIH

Roundtable Discussion and Q/A
- Dr. Eyasu Teshale, Division of Viral Hepatitis, US Centers for Disease Control and Prevention (CDC)
- Dr. Maria Garcia, General Viral & Hepatitis Branch, Center for Devices and Radiological Health, US Food and Drug Administration (FDA)
- Dr. T. Jake Liang, Liver Diseases Branch, NIDDK, NIH
- Dr. Patrizia Farci, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), NIH

Moderators:
- Dr. Jay Hoofnagle, NIDDK
- Dr. John Ward, Coalition for Global Hepatitis Elimination, Task Force for Global Health
Bios

Presenters

Jay Hoofnagle, MD
Director, Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH

Dr. Jay Hoofnagle is the Director of the Liver Disease Research Branch in the Division of Digestive Diseases and Nutrition of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). Dr. Hoofnagle is a hepatologist and gastroenterologist who had done laboratory and clinical research on liver diseases for the last 50 years, initially at the Food and Drug Administration in hepatitis B and subsequently at the NIH in hepatitis B, C and D, autoimmune liver diseases, nonalcoholic steatohepatitis, and drug-induced liver injury. He has published more than 400 original articles on liver disease. He is a former president of the American Association for the Study of Liver Disease and is the current editor-writer for the NIH-sponsored LiverTox website that provides clinical and research information on drug-induced liver disease.
Jeffrey Glenn, MD, PhD
Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering, Stanford University

Jeffrey Glenn is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused on studying molecular virology and the translation of that knowledge into novel antiviral strategies, as well as the development of new treatments for liver diseases and cancer. He is the founder of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), co-founder of Riboscience LLC, and founder of I-Cubed Therapeutics, local biotechnology companies developing several new classes of antiviral and anti-cancer drugs.

Glenn was born in Los Angeles, and grew up in Switzerland. He received his B.A. degree in Biochemistry and French Civilization from U.C. Berkeley from where he graduated summa cum laude. He received his M.D. and Ph.D. in Biochemistry and Biophysics from U.C.S.F.. He trained in internal medicine at Stanford University where he completed specialty training in gastroenterology and hepatology, and joined the faculty in 2000.

He is the principal investigator on multiple NIH grants, an inventor on numerous patents, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory.
Norah Terrault, MD, MPH, FAASLD
Professor of Medicine and Chief of Gastroenterology & Liver Diseases, Keck School of Medicine at the University of Southern California

Dr. Norah Terrault received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at University of Toronto and a Masters in Public Health at University of California Berkeley. She is currently Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. Dr. Terrault has focused her clinical and research activities on viral hepatitis and nonalcoholic fatty liver disease, especially in patients with cirrhosis and those with transplants. She has been PI on multiple NIH-funded studies. In addition, she is the founder of ECHO-Plus, a multifaceted program to train and support primary care physicians in California to care for patients with hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators.
Theo Heller, M.D. is Chief of the Translational Hepatology Section, Liver Diseases Branch, NIDDK at the NIH. He received an M.D. from the University of the Witwatersrand, South Africa and then underwent residency training in Internal Medicine at Georgetown University Hospital. He was then a postdoctoral fellow with Dr. Robert Purcell at the NIH and subsequently a Gastroenterology fellow at the University of Maryland. His Hepatology Fellowship was with Drs. T Jake Liang and Jay Hoofnagle at the NIH where he remained as faculty. Dr. Heller’s scientific interests cover clinical and translational work in humans and include Hepatitis D, factors causing the progression of liver disease, rare liver diseases, and the gut-liver axis. He has published over 200 scientific papers as well as guidelines for the management of chronic hepatitis C, management of healthcare workers living with viral hepatitis, Joubert Syndrome, Autosomal Recessive Polycystic Disease, and criteria for clinical trials in chronic graft versus host disease. He has received awards for mentoring including the Hugh H. Hussey Award from Georgetown University Hospital in 1993, recognition for education of postbaccalaureate trainees, the NIDDK Nancy Nossal Mentorship Award twice, the NIDDK “You Make A Difference” Award in 2010, and the faculty teacher of the year award, Department of Medicine, Division of Gastroenterology, University of Maryland in 2014. He is committed to medical and science education at all levels and has fostered diversity in his trainees. In addition, he has been honored with a NIH Plain Language Award in 2010, NIDDK Early Career Investigator Award by the sponsors of the Congressional Breakfast to honor the 60th anniversary of NIDDK in 2010, Fellow of the American Association for the Study of Liver Disease in 2017, a NIAID Merit Award in 2017, a NIDDK innovation award in 2019 and a NCI Director’s Award for Clinical Science in 2020. He has served as an editorial board member for *Gastroenterology*, and *Hepatology*. 
Discussants

Eyasu Teshale, MD  
Team Lead, Epidemiology and Research, Division of Viral Hepatitis, US CDC

Eyasu Teshale MD, is a team lead for the epidemiology and research team in the Division of Viral Hepatitis at the Centers for Disease Control and Prevention in Atlanta, Georgia. Teshale practiced medicine for 15 years in a resource limited setting. He began his CDC career as an Epidemic Intelligence Service Officer assigned to the Division of HIV/AIDS prevention from 2001-2003. Dr. Teshale has been working on viral hepatitis since 2007 and participated in outbreak investigations both domestically and internationally. Dr. Teshale has published extensively in the peer reviewed literature and authored many book chapters.

Maria Garcia, PhD  
Assistant Director, General Viral and Hepatitis, Center for Devices and Radiological Health, US Food and Drug Administration (FDA)

Dr. Garcia has been working at the FDA in the Division of Microbiology Devices for 10 years where she is currently the Assistant Director for General Viral and Hepatitis. She has been reviewing hepatitis serology and molecular diagnostic devices since she joined the FDA in 2011. She obtained her Ph.D. in Virology from Harvard in 2008 and her B.Sc. Biology from MIT in 2000.
T. Jake Liang, MD
Chief, Liver Diseases Branch and Deputy Director, Translational Research, National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH

T. Jake Liang, M.D. is currently the Chief of Liver Diseases Branch and Deputy Director of Translational Research, NIDDK, NIH. He graduated from Harvard College and received his MD degree from Harvard Medical School. He completed his internal medicine residency at the New York University/Bellevue Hospital Center, and a fellowship in gastroenterology and hepatology at Massachusetts General Hospital and Harvard Medical School, where he was an Assistant Professor of Medicine from 1990-1996. Dr. Liang is an internationally renowned and dominant thought leader in the field of viral hepatitis and liver diseases with diverse scientific expertise and editorial experience in virology, immunology, cell biology, therapeutics, regenerative medicine and genetics/genomics. He has made groundbreaking discoveries critical to understanding hepatitis C virus pathogenesis and treatment and to developing a novel approach to HCV vaccination. He has published over 300 scientific papers with many of them in high-impact journals including NEJM, Science, Nature, Nature Medicine, Science Trans Med, Nature Genetics, Annals of Int Med, J Clin Invest, etc., and edited numerous books. He has an H-index of 85. Dr. Liang has been an Associate Editor for Gastroenterology (IF 18)(1996-2001, 2016-2021), Hepatology (IF 11)(2001-2006) and Gut (IF 16)(2014-2017). He was elected to the American Society for Clinical Investigation (ASCI) in 1996, the Association of American Physicians in 2002, and the National Academy of Medicine in 2016. He has been active in many academic professional societies, including ASCI, the American Association for the Study of Liver Diseases (AASLD) and the American Gastroenterological Association (AGA). He was a member of the ASCI Council from 2004-2007. He was on the Governing Board of the AASLD from 2007 to 2012 and the President of the AASLD (2011). His outstanding contributions had been recognized with numerous accolades including the recipient of the British Liver Scholar Award, the Leon Schiff Lectureship, the Edward W. Morrow Lectureship, the Bruce Witte Distinguished Lecture Award, NIH KT Jeang Lectureship, NIH APAO Outstanding Scientific Achievement Award, NIDDK Nancy Nossal Scientific Mentorship Award, NIDDK Director’s Award and the AASLD Distinguished Mentor/Clinician Award.
Patrizia Farci, MD
Chief, Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), NIH

Dr. Farci earned her M.D. at the University of Cagliari Medical School, Italy, and then became a board-certified specialist in infectious diseases and gastroenterology at the same university. She was trained at the department of gastroenterology of the Molinette Hospital in Torino under Dr. Mario Rizzetto and at the department of medicine of the Royal Free Hospital School of Medicine in London under Professor Sheila Sherlock. In 1989, she joined the laboratory of Dr. Robert H. Purcell in the Laboratory of Infectious Diseases (LID) as a visiting scientist. In 1992, she became associate professor of medicine and, in 2000, full professor of medicine and director of the liver unit and of the postgraduate school of gastroenterology at the University of Cagliari. In 2007, she returned to LID, where in 2010 she became chief of the Hepatic Pathogenesis Section.
Moderators

John W. Ward, MD  
Director, Coalition for Global Hepatitis Elimination, Task Force for Global Health

Dr. John W. Ward created and directs the Coalition for Global Hepatitis Elimination of the Task Force for Global Health. Modelled after other Task Force programs to eliminate disease, the Coalition is a community of practice strengthening the capacity of national and sub-national hepatitis elimination programs through funding, advocacy, technical assistance, operational research and monitoring progress toward hepatitis elimination in >190 countries. Globally, Dr. Ward is an advisor to African Union Hepatitis Technical Working Group, and WHO including the PAHO technical advisory committee on disease elimination and the WPRO Hepatitis B Expert Resource Panel. Dr. Ward chairs the AASLD Task Force for Hepatitis Elimination. Over a 13-year tenure, Dr. Ward directed the US CDC Division of Viral Hepatitis with responsibilities for viral hepatitis surveillance, prevention, and research. At the national level, Dr. Ward developed recommendations for hepatitis A and hepatitis B vaccination, hepatitis B and hepatitis C screening, authored the first action plan for viral hepatitis prevention. Dr. Ward initiated the US Academies of Sciences recommendations for viral hepatitis elimination and guided the launch of pioneer HCV elimination programs. Earlier Dr. Ward was Editor of the CDC MMWR and assisted in the CDC response to large outbreaks including SARS and the anthrax attacks after 9/11. As a medical epidemiologist in the CDC HIV/AIDS program, Dr. Ward identified new routes of HIV transmission, evaluated the first HIV tests to protect the nation’s blood supply and led national HIV/AIDS surveillance. Dr. Ward has authored over 150 publications of scientific work in viral hepatitis and HIV and edited Silent Victories, a history of public health in the 20th Century published by Oxford University Press. Dr. Ward received his medical training at the University of Alabama at Birmingham and University of Washington, Seattle. Dr. Ward is a Professor in the Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta.